Research & Development
Predicine to present posters on liquid biopsy tech at ESMO
Predicine's liquid biopsy portfolio includes assays that provide translational insights to aid in potential cancer therapeutic strategies.
September 8, 2022
Nanostics launches bladder cancer study
Its ClarityDX bladder test uses extracellular vesicle detection technology and machine-learning model analysis to identify the most potent disease predictors for the early detection of bladder cancer.
July 19, 2022
C2i Genomics launches MRD test in Europe
The test is the first software-as-a-medical-device MRD test and will be available in countries accepting the CE Mark, according to the company. Recently, it received CE-IVD marking in the European Union, U.K., and Switzerland.
April 5, 2022
ASCO study touts data from bladder cancer clinical trial
The identification of a biomarker for predicting bladder cancer survival comes out the secondary part of the S1314 clinical trial, which measured long-term survival data in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery.
February 13, 2022
Natera launches new test for kidney rejection
The test is the only one on the market that provides three values -- the quantity of donor-derived cfDNA (dd-cfDNA), fraction of dd-cfDNA, and total cfDNA -- on every report, the company stated. Combining these three metrics has been shown to improve sensitivity when evaluating transplant rejection, compared to using dd-cfDNA fraction alone, Natera said.
September 8, 2021
Google reports pathology AI helps predict survival in cancer patients
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
Natera touts liquid biopsy in bladder cancer
Researchers evaluated use of the test in 68 patients with muscle invasive bladder cancer who received neoadjuvant chemotherapy before cystectomy at Aarhus University in Denmark. They examined a total of 656 blood samples taken at the time of diagnosis, during chemotherapy treatment, before cystectomy, and in post-treatment monitoring.
May 8, 2019
Page 1 of 1